FollowFilings The Ledger · @followfilings · data: SEC Form 4 ← All receipts

$INBX

Inhibrx Biosciences, Inc.
$90.50 +151.8% vs prior close

What they do: Biological Products, (No Diagnostic Substances) · Exchange: Nasdaq · Employees: 109

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. (via Yahoo Finance)

Earnings trend (from SEC filings)

Quarter endRevenueDiluted EPS
2024-06-30$100K—
2024-09-30$0$-2.84
2025-03-31$0$-2.80
2025-06-30$1.3M$-1.85
2025-09-30$0$-2.28
2026-06-30$0$-2.34

Institutional ownership (via Yahoo Finance, 13F-derived)

Insiders hold: 23.08% · Institutions hold: 90.66% across 224 filers

InstitutionSharesValue% held
Morgan Stanley1,308,051$118.4M8.89%
Perceptive Advisors Llc1,297,763$117.4M8.82%
Sanofi1,157,926$104.8M7.87%
Viking Global Investors, L.P.1,123,929$101.7M7.64%
HighTower Advisors, LLC870,551$78.8M5.92%
Bank of America Corporation841,141$76.1M5.72%
Blackrock Inc.825,972$74.8M5.61%
Schonfeld Strategic Advisors Llc697,586$63.1M4.74%

Charts (2)

$INBX chart
auto
$INBX chart
2026-10-15 17:13

Insider activity — every transaction, real date, real price

Trade dateFiledNameRoleActionSharesPriceValueStock since
2026-10-142026-10-14Lappe MarkChief Executive OfficerBOUGHT100$85.76$9K+6.1%
2026-10-142026-10-14Lappe MarkChief Executive OfficerBOUGHT2,449$84.07$206K+6.1%
2026-10-142026-10-14Lappe MarkChief Executive OfficerBOUGHT2,451$85.00$208K+6.1%
2026-10-142026-10-14Lappe MarkChief Executive OfficerBOUGHT2,470$84.07$208K+6.1%
2026-10-142026-10-14Lappe MarkChief Executive OfficerBOUGHT2,470$85.00$210K+6.1%

Our calls

PostedTweetPrice at postNowSince post
2026-10-15 17:12$INBX — CEO Mark Lappe bought $849K of Inhibrx Biosciences (10,040 sh). A biotec$90.50$90.50+0.0%